New treatment options for Toxoplasmosis in patients with AIDS
Novel Therapeutic Strategies for ELQ-422, a preclinical Toxoplasmosis Drug Candidate
This study is testing a new drug called ELQ-422 to help people with AIDS who have Toxoplasmosis, aiming to make treatment safer and more effective by targeting the parasite that causes the infection and reducing harmful brain cysts.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Portland VA Medical Center NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10951522 on NIH RePORTER |
What this research studies
This research focuses on developing a new drug, ELQ-422, to treat Toxoplasmosis, particularly in patients with AIDS who are at higher risk for this infection. The study aims to create a safer and more effective therapy that not only treats acute infections but also reduces or eliminates brain tissue cysts associated with the disease. By using a novel class of compounds called endochin-like quinolones, the research investigates how these drugs can inhibit the replication of the Toxoplasma gondii parasite. The goal is to improve patient outcomes by minimizing adverse effects commonly seen with current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with AIDS who are at risk for Toxoplasmosis or have experienced related complications.
Not a fit: Patients who do not have AIDS or are not at risk for Toxoplasmosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment for Toxoplasmosis, significantly improving the health and quality of life for patients with AIDS.
How similar studies have performed: Previous research has shown promising results with similar drug classes in preclinical models, indicating potential for success in treating Toxoplasmosis.
Where this research is happening
Portland, United States
- Portland VA Medical Center — Portland, United States (Active)
Researchers
- Principal investigator: Doggett, Joseph Stone — Portland VA Medical Center
- Study coordinator: Doggett, Joseph Stone
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.